Clinical Trials Directory

Trials / Unknown

UnknownNCT06169553

The Injection-Related InfectionS (IRIS) Program

The IRIS Program: A Novel Pathway to Optimize Treatment of Injection-related Infections for People Who Inject Drugs in Hamilton, Ontario

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
McMaster University · Academic / Other
Sex
All
Age
16 Years – 105 Years
Healthy volunteers
Not accepted

Summary

People who inject drugs are at risk of injection-related infections, like abscesses or infective endocarditis. The Injection-Related InfectionS (IRIS) program hopes to improve treatment for participants by providing a low-barrier, one-stop shop model for people who inject drugs who experience injection-related infections to access more holistic and compassionate care. IRIS is a non-randomized clinical trial, meaning that it offers a specific program to eligible patients. This program offers care for substance use and infectious disease with additional peer support and systems navigation, if interested. The investigators anticipate enrolling 80 participants in the intervention and will follow participants throughout the infection treatment period (estimated 6-12 weeks). The investigators will collect information at the time of enrolment, at the 6-month mark, and monthly via electronic medical chart review. The investigators will use an interrupted time series analysis to evaluate the impact of the intervention on rates of treatment completion, emergency department visits, hospitalizations, and death, before versus after the intervention.

Conditions

Interventions

TypeNameDescription
OTHERHolistic injection-related injection treatmentParticipants in the intervention group will be provided additional supports to address their social and medical needs, including infectious disease management, addictions medicine, peer support, and systems navigation. Each participant will receive individualized care depending on their unique needs.

Timeline

Start date
2024-01-01
Primary completion
2025-09-01
Completion
2025-12-01
First posted
2023-12-13
Last updated
2023-12-13

Locations

2 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT06169553. Inclusion in this directory is not an endorsement.